| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
CD117 (c-kit), IHC with Interpretation
Test Code11230X
CPT Codes
88342
Preferred Specimen
Formalin-fixed, paraffin-embedded tissue in an IHC specimen transport kit
Other Acceptable Specimens
4-micron unstained slides • Fixed tissue • Tissue in neutral buffered formalin
Instructions
Pathology report is required
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Indefinite
Refrigerated: Indefinite
Frozen: Unacceptable
Refrigerated: Indefinite
Frozen: Unacceptable
Methodology
Immunohistochemistry (IHC)
Setup Schedule
A.M.
Clinical Significance
Testing for CD117/c-kit expression may be a useful tool for the identification of several malignant neoplasma expressing c-kit, including gastrointestinal stromal tumors (GISTS), mast cell diseases, acute myeloid leukemia (AML), small cell lung carcinoma (SCLC), and Ewing's sarcoma. It may also aid in differentiating gastrointestinal stromal tumors (GISTS) from other intra-abdominal mesenchymal tumors.
Recent studies have indicated that the tyrosine kinase inhibitor, STI571 (Gleeva), may be effective in treating CD117/c-kit positive tumors. Therefore, testing tumors for CD117/c-kit immunoreactivity can assist in both diagnosis and the prediction of drug sensitivity to tyrosine kinase inhibitor STI571 treatment.
Recent studies have indicated that the tyrosine kinase inhibitor, STI571 (Gleeva), may be effective in treating CD117/c-kit positive tumors. Therefore, testing tumors for CD117/c-kit immunoreactivity can assist in both diagnosis and the prediction of drug sensitivity to tyrosine kinase inhibitor STI571 treatment.
